-
货号
KDD00601
-
描述
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD142 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Tisotumab in the sample competitively binds to the pre-coated protein with biotin-labeled Tisotumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tisotumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
应用
Used for the quantitative determination of Tisotumab concentration in serum and plasma. -
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
156.25 - 10,000 ng/mL -
灵敏度
159.18 ng/mL -
精准度
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
Intra-Assay Precision
Inter-Assay Precision
Sample
1
2
3
1
2
3
n
16
16
16
24
24
24
Mean (ng/mL)
3888.5
1175.5
271.1
4051.6
1179.5
249.5
Standard deviation
284.5
59.7
22.1
369.4
89.4
34.2
CV (%)
7.3
5.1
8.2
9.1
7.6
13.7
-
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. -
别名
HuMax-TF-ADC, TF-011-MMAE, HuMax-TF, CAS: 1418628-81-5
-
背景
Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Based on its high expression on many solid tumors (including ovarian, prostate, bladder, esophageal, endometrial and lung) and its rapid internalization, TF is considered a suitable target for antibody-drug conjugates. In pre-clinical trials tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth. Genmab and Seattle Genetics are jointly developing tisotumab vedotin. In a Phase IIa study, preliminary data demonstrated a manageable safety profile and encouraging efficacy (ORR 37%) in relapsed, recurrent or metastatic cervical cancer.
